Superluminal Medicines Announces Formation of Scientific Advisory Board Superluminal Medicines, Inc. announced the formation of its Scientific Advisory Board (SAB).

Superluminal Medicines Closes $120 Million Series A Round Superluminal Medicines, Inc. announced the closing of a $120 million Series A funding round.

Superluminal Medicines Launches with $33 Million Seed Round to Fuel its Drug Discovery Engine and Pipeline of Small Molecule Therapeutics Financing led by RA Capital Management with participation from Insight Partners, NVIDIA, and Gaingels Superluminal combines deep biology and chemistry expertise with machine learning built on vast...